Literature DB >> 22109667

Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer.

Anne-Sophie Bats1, Florent Hugonnet, Cyrille Huchon, Chérazade Bensaid, Nadia Pierquet-Ghazzar, Marc Faraggi, Fabrice Lécuru.   

Abstract

PURPOSE: To evaluate the prognostic significance of increased mediastinal (18)F-FDG uptake in PET/CT for the staging of advanced ovarian cancer.
METHODS: We retrospectively evaluated patients managed for FIGO stage III/IV ovarian cancer between 1 January 2006 and 1 June 2009. Patients were included if they had undergone (18)F-FDG PET/CT and surgery for initial staging. Exclusion criteria were age younger than 18 years, inability to undergo general anaesthesia, recurrent ovarian cancer, and borderline or nonepithelial malignancy. Whole-body PET/CT was performed after intravenous (18)F-FDG injection. The location of abnormal hot spots and (18)F-FDG maximal standard uptake values (SUV(max)) were recorded. We compared the complete cytoreduction and survival rates in groups defined based on mediastinal (18)F-FDG uptake and SUV(max) values. Kaplan-Meier curves of overall survival and disease-free survival were compared using the log-rank test. Hazard ratios with their 95% confidence intervals were computed. Adjusted hazard ratios were obtained using a multivariate Cox model.
RESULTS: We included 53 patients, of whom 17 (32%) had increased mediastinal (18)F-FDG uptake. Complete cytoreduction was achieved in 14 (87.5%) of the 16 patients managed with primary surgery and in 21 (75%) of the 28 patients managed with interval surgery. Complete cytoreduction was achieved significantly more often among patients without increased mediastinal (18)F-FDG uptake (80.6% vs. 35.3%; p = 0.001). Disease-free survival was comparable between the two groups. By univariate analysis, overall mortality was significantly higher among patients with increased mediastinal (18)F-FDG uptake (hazard ratio 5.70, 95% confidence interval 1.74-18.6). The only factor significantly associated with overall survival by multivariate analysis was complete cytoreduction (adjusted hazard ratio 0.24, 95% confidence interval 0.07-0.89).
CONCLUSION: Increased mediastinal (18)F-FDG uptake was common in patients with advanced ovarian cancer. However, complete cytoreduction, which was significantly more frequent among patients without mediastinal (18)F-FDG uptake, was the only factor independently associated with survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22109667     DOI: 10.1007/s00259-011-1984-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  17 in total

1.  Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.

Authors:  Valentin Kolev; Svetlana Mironov; Oleg Mironov; Nicole Ishill; Chaya S Moskowitz; Ginger J Gardner; Douglas A Levine; Hedvig Hricak; Richard R Barakat; Dennis S Chi
Journal:  Int J Gynecol Cancer       Date:  2010-08       Impact factor: 3.437

2.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

3.  Lymphatic drainage of the diaphragmatic pleura to the peritracheobronchial lymph nodes.

Authors:  G Okiemy; C Foucault; C Avisse; G Hidden; M Riquet
Journal:  Surg Radiol Anat       Date:  2003-04-04       Impact factor: 1.246

4.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

Authors:  D S Chi; E L Eisenhauer; J Lang; J Huh; L Haddad; N R Abu-Rustum; Y Sonoda; D A Levine; M Hensley; R R Barakat
Journal:  Gynecol Oncol       Date:  2006-05-22       Impact factor: 5.482

5.  Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.

Authors:  Eun Ji Nam; Mi Jin Yun; Young Taik Oh; Jae Wook Kim; Jae Hoon Kim; Sunghoon Kim; Yong Wook Jung; Sang Wun Kim; Young Tae Kim
Journal:  Gynecol Oncol       Date:  2009-11-18       Impact factor: 5.482

6.  Pathological diagnosis and cytoreduction of cardiophrenic lymph node and pleural metastasis in ovarian cancer patients using video-assisted thoracic surgery.

Authors:  Myong Cheol Lim; Hyun-Sung Lee; Dae Chul Jung; Ji Young Choi; Sang-Soo Seo; Sang-Yoon Park
Journal:  Ann Surg Oncol       Date:  2009-04-30       Impact factor: 5.344

7.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.

Authors:  Scott M Eisenkop; Nick M Spirtos; Richard L Friedman; Wei-Chien Michael Lin; Albert L Pisani; Sergio Perticucci
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

8.  The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

9.  Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer.

Authors:  X Deffieux; D Castaigne; C Pomel
Journal:  Int J Gynecol Cancer       Date:  2006 Jan-Feb       Impact factor: 3.437

10.  Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.

Authors:  S Risum; C Høgdall; A Loft; A K Berthelsen; E Høgdall; L Nedergaard; L Lundvall; S A Engelholm
Journal:  Gynecol Oncol       Date:  2007-12-04       Impact factor: 5.482

View more
  5 in total

Review 1.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 2.  Diagnostic performance of PET/CT and PET/MR in the management of ovarian carcinoma-a literature review.

Authors:  Mayur Virarkar; Dhakshinamoorthy Ganeshan; Anjalie Tara Gulati; Sarah Palmquist; Revathy Iyer; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2020-11-11

Review 3.  Systematic Review on the Accuracy of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography/Magnetic Resonance Imaging in the Management of Ovarian Cancer: Is Functional Information Really Needed?

Authors:  Subapriya Suppiah; Wing Liong Chang; Hasyma Abu Hassan; Chalermrat Kaewput; Andi Anggeriana Andi Asri; Fathinul Fikri Ahmad Saad; Abdul Jalil Nordin; Sobhan Vinjamuri
Journal:  World J Nucl Med       Date:  2017 Jul-Sep

4.  Radiomics Analysis of PET and CT Components of 18F-FDG PET/CT Imaging for Prediction of Progression-Free Survival in Advanced High-Grade Serous Ovarian Cancer.

Authors:  Xihai Wang; Zaiming Lu
Journal:  Front Oncol       Date:  2021-04-13       Impact factor: 6.244

5.  Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Authors:  Matthias Scheffler; Thomas Zander; Lucia Nogova; Carsten Kobe; Deniz Kahraman; Markus Dietlein; Irini Papachristou; Lukas Heukamp; Reinhard Büttner; Ron Boellaard; Adriaan A Lammertsma; Silvia Querings; Erich Stoelben; Walburga Engel-Riedel; Bernd Neumaier; Jürgen Wolf
Journal:  PLoS One       Date:  2013-01-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.